Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
156 studies found for:    PTEN
Show Display Options
Rank Status Study
1 Recruiting Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Conditions: PTEN;   ASD;   Autism;   Macrocephaly;   PTEN Hamartoma Tumor Syndrome
2 Not yet recruiting RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN)
Conditions: PTEN Gene Mutation;   PTEN Hamartoma Tumor Syndrome
Interventions: Drug: RAD001;   Drug: Placebo
3 Recruiting The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Condition: Prostate Cancer
4 Unknown  Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients
Conditions: Critical Illness;   Hyperglycemia
5 Completed Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer
Condition: Endometrial Neoplasms
Interventions: Behavioral: questionnaire;   Procedure: Blood sample-DNA testing / Tumour-genetic markers
6 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
7 Withdrawn PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
Condition: Ovarian Cancer
Intervention: Procedure: immunohistochemical, methylation, gene transfection
8 Completed A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Condition: Cancer
Intervention: Drug: GSK2636771
9 Completed
Has Results
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Conditions: Cowden's Disease;   Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18;   Drug: sirolimus;   Other: Clinical Videography
10 Not yet recruiting Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Metastatic Melanoma
Interventions: Drug: GSK2636771;   Drug: Pembrolizumab
11 Active, not recruiting Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Condition: Breast Cancer
Intervention: Genetic: BRCA1 BRCA2 PTEN PALB2 mutation
12 Active, not recruiting Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Pazopanib;   Drug: Everolimus
13 Recruiting Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Condition: Prostate Cancer
14 Recruiting Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null
Conditions: Cancer;   Solid Tumors
Intervention: Drug: ARQ 751
15 Recruiting Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: Copanlisib;   Drug: Cetuximab
16 Unknown  Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?
Conditions: Low Ovarian Reserve;   Poor Responders to Gonadotropihins Treatment
Intervention: Other: Removal of half an ovary
17 Active, not recruiting Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Condition: Breast Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
18 Completed Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
Condition: Solid Tumor
Intervention: Drug: everolimus
19 Withdrawn A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
Condition: Endometrial Cancer
Intervention: Drug: BMN 673
20 Completed Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Condition: c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Interventions: Drug: INC280;   Drug: Buparlisib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.